DHS 157.67(12)(c)2.a.a. The output for one typical set of operating conditions measured with the dosimetry system described in sub. (6) (b). DHS 157.67(12)(c)2.b.b. The difference between the measurement made in subd. 2. a. and the anticipated output expressed as a percentage of the anticipated output. DHS 157.67(12)(d)(d) To satisfy the requirements of par. (a) 2. and 3., a spot-check shall assure proper operation of all of the following: DHS 157.67(12)(d)1.1. Electrical interlocks at each gamma stereotactic radiosurgery room entrance. DHS 157.67(12)(d)2.2. Source exposure indicator lights on the gamma stereotactic radiosurgery unit, on the control console and in the facility. DHS 157.67(12)(e)(e) A licensee shall arrange for prompt repair of any system identified in par. (c) or (d) that is not operating properly. DHS 157.67(12)(f)(f) If the results of the checks required in par. (d) indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace or check the malfunctioning system. DHS 157.67(13)(13) Additional technical requirements for mobile remote afterloader units. DHS 157.67(13)(a)(a) A licensee providing mobile remote afterloader service shall do all of the following: DHS 157.67(13)(a)1.1. Check survey instruments before medical use at each client’s address of use or on each day of use, whichever is more frequent. DHS 157.67(13)(b)(b) In addition to the periodic spot-checks required by sub. (11), a licensee authorized to use mobile afterloaders for medical use shall perform checks on each remote afterloader unit before use at each address. A check shall be made to verify the operation of all the following: DHS 157.67(13)(b)2.2. Source exposure indicator lights on the remote afterloader unit, on the control console and in the facility. DHS 157.67(13)(b)4.4. Applicators, source transfer tubes and transfer tube-applicator interfaces. DHS 157.67(13)(b)7.7. Radiation monitors used to indicate whether the source has returned to a safe shielded position. DHS 157.67(13)(c)(c) A licensee shall ensure overall proper operation of the remote afterloader unit by conducting a simulated cycle of treatment before use at each address of use. DHS 157.67(13)(d)(d) If the results of the checks required in par. (b) indicate the malfunction of any system, a licensee shall lock the control console in the off position and not use the unit except as may be necessary to repair, replace or check the malfunctioning system. DHS 157.67(14)(a)(a) In addition to the survey requirement in s. DHS 157.25 (1), a person licensed to possess or use photon emitting remote afterloader, teletherapy or gamma stereotactic radiosurgery units shall perform surveys of the device and ensure the results of the surveys from the surface of the main source safe, with the sources in the shielded position, do not exceed the maximum and average radiation levels listed in the sealed source and device registry. DHS 157.67(14)(b)(b) A licensee shall make the survey required by par. (a) at installation of a new source and following repairs to source shielding, a source driving unit or other electronic or mechanical component that could expose a source, reduce the shielding around a source or compromise the radiation safety of the unit or a source. DHS 157.67(15)(15) Full inspection for teletherapy and gamma stereotactic radiotherapy units. DHS 157.67(15)(a)(a) A licensee shall have each teletherapy unit and gamma stereotactic radiosurgery unit inspected for proper operation and serviced during source replacement to assure proper functioning of the source exposure mechanism. The intervals between full inspection and servicing shall not to exceed 5 years for each teletherapy unit and shall not exceed 7 years for each gamma stereotactic radiosurgery unit. DHS 157.67(15)(b)(b) Inspection and servicing of a teletherapy or gamma stereotactic radiosurgery unit may only be performed by a person specifically licensed to do so by the department, the NRC or another agreement state. DHS 157.67(16)(16) Therapy-related computer systems. A licensee shall perform acceptance testing on the treatment planning system under published protocols accepted by nationally recognized bodies. The acceptance testing shall include, as applicable, verification of all of the following: DHS 157.67(16)(a)(a) Source-specific input parameters required by the dose calculation algorithm used to calculate the dose to the patient. DHS 157.67(16)(b)(b) Accuracy of dose, dwell time of the radioactive source at a particular location and treatment time calculations at representative points. DHS 157.67(16)(c)(c) Accuracy of isodose graphic plots on paper and graphic displays. DHS 157.67(16)(d)(d) Accuracy of the software used to determine radioactive source positions from radiographic images. DHS 157.67(16)(e)(e) Accuracy of electronic transfer of the treatment delivery parameters to the treatment delivery unit from the treatment planning system that was used to calculate the patient dose and radioactive source dwell times. DHS 157.67 NoteNote: An example of such a nationally recognized body is the American Association of Physicists in Medicine.
DHS 157.67(17)(17) Training for use of remote afterloader, teletherapy and gamma stereotactic radiosurgery units. A licensee shall require an authorized user of a sealed source for a use authorized under sub. (1) to have received training in device operation, safety procedures, and clinical use for the type of use for which authorization is sought. This training requirement may be satisfied by successful completion of a training program provided by the vendor for new users or by receiving training supervised by an authorized user or authorized medical physicist, as appropriate, who is authorized for the type of use for which the individual is seeking authorization. Except as provided in s. DHS 157.61 (10), a licensee shall require an authorized user of a sealed source for a use authorized under sub. (1) to be a physician who meets any of the following requirements: DHS 157.67(17)(a)(a) Is certified by a medical specialty board whose certification process has been recognized by the department, the NRC or an agreement state. To have its certification process recognized, a specialty board shall require all candidates for certification to do all of the following: DHS 157.67(17)(a)1.1. Successfully complete a minimum of 3 years of residency training in a radiation therapy program approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council of Postdoctoral Training of the American Osteopathic Association. DHS 157.67(17)(a)2.2. Pass an examination, administered by diplomates of the specialty board, which tests knowledge and competence in radiation safety, radionuclide handling, treatment planning, quality assurance, and clinical use of stereotactic radiosurgery, remote afterloaders and external beam therapy. DHS 157.67 NoteNote: Specialty boards whose certification processes have been recognized by the Department, the NRC or an agreement state will be posted on the NRC’s web site at www.nrc.gov. DHS 157.67(17)(b)(b) Has completed a structured educational program in basic radionuclide techniques applicable to the use of a sealed source in a therapeutic medical unit that includes all of the following: DHS 157.67(17)(b)1.1. Two hundred hours of classroom and laboratory training in all the following areas: DHS 157.67(17)(b)2.2. Five hundred hours of work experience, under the supervision of an authorized user who meets the requirements in this subsection, s. DHS 157.61 (10), or equivalent NRC or agreement state requirements at a medical facility authorized to use byproduct materials under sub. (1), involving all of the following: DHS 157.67(17)(b)2.c.c. Using administrative controls to prevent a medical event involving the use of radioactive material. DHS 157.67(17)(b)2.d.d. Implementing emergency procedures to be followed in the event of the abnormal operation of the medical unit or console. DHS 157.67(17)(b)3.3. Three years of supervised clinical experience in radiation therapy under an authorized user who meets the requirements in this subsection, s. DHS 157.61 (10), or equivalent NRC or agreement state requirements, as part of a formal training program approved by the Residency Review Committee for Radiation Oncology of the Accreditation Council for Graduate Medical Education or Royal College of Physicians and Surgeons of Canada or the Committee on Postdoctoral Training of the American Osteopathic Association. This experience may be obtained concurrently with the supervised work experience required by subd. 2. DHS 157.67(18)(18) Written attestation. A licensee shall require an authorized user of a sealed source for a use authorized under sub. (17) to have obtained written attestation that the individual has successfully completed the requirements in sub. (17) (b), and has achieved a level of competency sufficient to function independently as an authorized user of each type of therapeutic medical unit for which the individual is requesting authorized user status. The attestation must be obtained from either of the following: DHS 157.67(18)(a)(a) A preceptor authorized user who meets the requirements in sub. (17), s. DHS 157.61 (10), or equivalent NRC or agreement state requirements for an authorized user for each type of therapeutic medical unit for which the individual is requesting authorized user status. DHS 157.67(18)(b)(b) . A residency program director who affirms in writing that the attestation represents the consensus of the residency program faculty where at least one faculty member is an authorized user who meets the requirements in sub. (17), s. DHS 157.61 (10), or equivalent NRC or agreement state requirements user for each type of therapeutic medical unit for which the individual is requesting authorized user status. The residency training program must be approved by the Residency Review Committee of the Accreditation Council for Graduate Medical Education or the Royal College of Physicians and Surgeons of Canada or the Council on Postdoctoral Training of the American Osteopathic Association and must include training and experience specified in sub. (17) (b). DHS 157.67 HistoryHistory: CR 01-108: cr. Register July 2002 No. 559, eff. — see Note at the start of the chapter; correction in (4) (f) made under s. 13.93 (2m) (b) 7., Stats., Register July 2002 No. 559; CR 06-021: am. (9) (b) 2., 3., 6., 8. and 10., r. and recr. (17), cr. (18) Register September 2006, No. 609, eff. 10-1-06; CR 09-062: am. (8) (b) 1., (17) (b) 2. (intro.), 3. and (18) Register April 2010 No. 652, eff. 5-1-10; CR 16-078: am. (11) (f), (12) (b) 3. Register January 2018 No. 745, eff. 2-1-18; CR 22-015: r. (1) (intro.), renum. (1) (a) to (1) (a) (intro.) and am., cr. (1) (a) 1., renum. (1) (b) to (1) (a) 2. and am., cr. (1) (b), am. (4) (d) (intro.), (e), cr. (4) (g), (h), am. (15) (title), (a), (17) (intro.), (a) (intro.), 1., (b) 2. (intro.), 3., cr. (17) (b) 4., renum. (18) to (18) (intro.) and am., cr. (18) (a), (b) Register June 2023 No. 810, eff. 7-1-23; correction in numbering of (4) (h) made under s. 13.92 (4) (b) 1., Stats., Register June 2023 No. 810. DHS 157.68DHS 157.68 Radioactive drugs for medical use. DHS 157.68(1)(1) Preparation. A licensee authorized to manufacture, prepare or transfer for commercial distribution or noncommercial transfer to medical use licensees in a consortium radioactive drugs shall ensure that any individual preparing the drugs is one of the following: DHS 157.68(1)(b)(b) An individual under the supervision of an authorized nuclear pharmacist. DHS 157.68(1)(c)2.2. Is identified as an authorized nuclear pharmacist on a license issued by the department, an agreement state or the NRC. DHS 157.68(1)(c)3.3. Is identified as an authorized nuclear pharmacist by a licensee who is authorized by the department, an agreement state or the NRC to designate authorized nuclear pharmacists operating under their license. DHS 157.68(1)(c)4.4. Functioned as a nuclear pharmacist preparing only radioactive drugs containing accelerator-produced radioactive material, and practiced at a pharmacy at a government agency or federally recognized Indian Tribe before November 30, 2007 or at all other locations of use before August 8, 2009. DHS 157.68(2)(2) Documentation. A licensee shall provide to the department a copy of all the following, as appropriate: DHS 157.68(2)(a)(a) A copy of each individual’s certification by a specialty board whose certification process has been recognized by the department, the NRC, or an agreement state as specified in s. DHS 157.61 (9). DHS 157.68(2)(e)(e) The state pharmacist licensure, no later than 30 days after the date that the licensee allows, under sub. (1) (c) 1. and 2., the individual to work as an authorized nuclear pharmacist. DHS 157.68(2)(f)(f) Documentation that only accelerator-produced radioactive materials were used in the practice of nuclear pharmacy at a government agency or federally recognized Indian Tribe before November 30, 2007 or at all other locations of use before August 8, 2009. DHS 157.68 HistoryHistory: CR 06-021: cr. Register October 2006 No. 610, eff. 11-1-06; CR 09-062: am. (1) (intro.) and (2) (e), cr. (1) (c) 4. and (2) (f) Register April 2010 No. 652, eff. 5-1-10; CR 22-015: am. (2) (a) Register June 2023 No. 810, eff. 7-1-23. DHS 157.70DHS 157.70 Other medical uses of radioactive material or radiation from radioactive material. A licensee may use radioactive material or a radiation source approved for medical use that is not specifically addressed in ss. DHS 157.63 to 157.67 if all of the following criteria are met:
/exec_review/admin_code/dhs/110/157
true
administrativecode
/exec_review/admin_code/dhs/110/157/vi/67/13/c
Department of Health Services (DHS)
Chs. DHS 110-199; Health
administrativecode/DHS 157.67(13)(c)
administrativecode/DHS 157.67(13)(c)
section
true
